卡麦角林与静脉注射白蛋白预防卵巢过度刺激综合征的比较：一项随机临床试验。
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
机构信息
Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat Highway, Tehran, Iran.
出版信息
J Assist Reprod Genet. 2012 Mar;29(3):259-64. doi: 10.1007/s10815-011-9708-4. Epub 2012 Jan 10.
Abstract
PURPOSE
To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.
METHODS
In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.
RESULTS
Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).
CONCLUSIONS
Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients.
摘要
目的
比较卡麦角林（Cb2）和静脉用人血白蛋白（HA）预防卵巢过度刺激综合征的疗效。
方法
在这项随机对照试验研究中，将 138 名有发生 OHSS 高风险的妇女随机分为两组。在第 1 组中，静脉输注 20%的 20 克 HA，持续 1 小时。第 2 组在取卵日开始每天口服 0.5 毫克 Cb2，共 7 天。所有患者在取卵后 7 天和 14 天进行随访，以确定早期临床或超声 OHSS 证据。
结果
HA 组和 Cb2 组分别有 33 例和 14 例出现中度 OHSS，差异有统计学意义。HA 组重度 OHSS 例数明显高于 Cb2 组（P < 0.001）。
结论
在高危患者中，预防性口服低剂量卡麦角林预防 OHSS 的效果优于静脉用人血白蛋白，且成本更低。
相似文献
1
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
J Assist Reprod Genet. 2012 Mar;29(3):259-64. doi: 10.1007/s10815-011-9708-4. Epub 2012 Jan 10.
2
Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study.
J Obstet Gynaecol. 2022 Jan;42(1):122-126. doi: 10.1080/01443615.2020.1870944. Epub 2021 Jul 16.
3
Cabergoline for preventing ovarian hyperstimulation syndrome.
Cochrane Database Syst Rev. 2012 Feb 15(2):CD008605. doi: 10.1002/14651858.CD008605.pub2.
4
Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):439-43. doi: 10.1016/j.ejogrb.2013.07.010. Epub 2013 Aug 8.
5
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Cochrane Database Syst Rev. 2016 Nov 30;11(11):CD008605. doi: 10.1002/14651858.CD008605.pub3.
6
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
Reprod Biomed Online. 2008 Dec;17(6):751-5. doi: 10.1016/s1472-6483(10)60401-4.
7
Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
Arch Gynecol Obstet. 2013 Nov;288(5):1159-63. doi: 10.1007/s00404-013-2875-z. Epub 2013 May 16.
8
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
J Ovarian Res. 2016 May 17;9(1):29. doi: 10.1186/s13048-016-0237-8.
9
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
Int J Gynaecol Obstet. 2018 Feb;140(2):217-222. doi: 10.1002/ijgo.12360. Epub 2017 Nov 9.
10
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
J Gynecol Obstet Hum Reprod. 2017 Jan;46(1):87-91. doi: 10.1016/j.jgyn.2016.04.002. Epub 2016 May 27.
引用本文的文献
1
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes.
Reprod Biol Endocrinol. 2023 Aug 1;21(1):70. doi: 10.1186/s12958-023-01120-7.
2
Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.
Front Endocrinol (Lausanne). 2022 Jan 26;13:808517. doi: 10.3389/fendo.2022.808517. eCollection 2022.
3
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Cochrane Database Syst Rev. 2021 Apr 14;4(4):CD008605. doi: 10.1002/14651858.CD008605.pub4.
4
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.
Iran J Med Sci. 2018 May;43(3):248-260.
5
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Cochrane Database Syst Rev. 2016 Nov 30;11(11):CD008605. doi: 10.1002/14651858.CD008605.pub3.
6
Volume expanders for the prevention of ovarian hyperstimulation syndrome.
Cochrane Database Syst Rev. 2016 Aug 31;2016(8):CD001302. doi: 10.1002/14651858.CD001302.pub3.
7
Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.
Sci Rep. 2016 Jan 11;6:19093. doi: 10.1038/srep19093.
8
Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.
Avicenna J Med. 2015 Oct-Dec;5(4):123-7. doi: 10.4103/2231-0770.165121.
9
Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction.
J Res Med Sci. 2015 Jul;20(7):692-6. doi: 10.4103/1735-1995.166228.
10
Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.
Iran J Reprod Med. 2013 Oct;11(10):837-42.
本文引用的文献
1
Physiology and pathology of ovarian hyperstimulation syndrome.
Semin Reprod Med. 2010 Nov;28(6):448-57. doi: 10.1055/s-0030-1265670. Epub 2010 Nov 16.
2
Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis.
Fertil Steril. 2011 Jan;95(1):188-96, 196.e1-3. doi: 10.1016/j.fertnstert.2010.05.026. Epub 2010 Jul 1.
3
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Acta Obstet Gynecol Scand. 2010 May;89(5):692-9. doi: 10.3109/00016341003592537.
4
Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis.
Hum Reprod Update. 2010 Sep-Oct;16(5):459-66. doi: 10.1093/humupd/dmq006. Epub 2010 Mar 30.
5
Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels.
Int J Gynaecol Obstet. 2010 Feb;108(2):159-60. doi: 10.1016/j.ijgo.2009.09.017. Epub 2009 Nov 7.
6
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
Reprod Biomed Online. 2008 Dec;17(6):751-5. doi: 10.1016/s1472-6483(10)60401-4.
7
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
Hum Reprod. 2007 Dec;22(12):3210-4. doi: 10.1093/humrep/dem315. Epub 2007 Oct 4.
8
Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.
Hum Fertil (Camb). 2007 Jun;10(2):75-85. doi: 10.1080/14647270601111239.
9
Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study.
Fertil Steril. 2007 Oct;88(4):982-5. doi: 10.1016/j.fertnstert.2006.11.170. Epub 2007 Feb 20.
10
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Endocrinology. 2006 Nov;147(11):5400-11. doi: 10.1210/en.2006-0657. Epub 2006 Aug 10.
Zotero 插件